Login
E-mail
Password
Mostra password
Ricorda
Password dimenticata?
Iscriviti gratuitamente
Registrazione
Registrazione
Parametri
Parametri
Quotazioni dinamiche 
OFFON

I Leader della Finanza

Ultime notizieSocietąMercatiEconomia & ForexMaterie PrimeTassiLeader della FinanzaPro. della FinanzaAgendaSettori 
HomeTutte le notizieLe notizie pił letteBiografie dei Leader della finanza
Riassunto 
Founder of 6 different companies, including: Syndax Pharmaceuticals, Inc., Oric Pharmaceuticals, Inc. and Metacrine, Inc. Richard A. Heyman is an entrepreneur and businessperson who has been at the helm of 7 different companies and is Chairman of PMV Pharmaceuticals, Inc., Chairman of Metacrine, Inc. (which he founded in 2014), Chairman at Amunix Pharmaceuticals, Inc. and Venture Partner at ARCH Venture Partners LLC.

He is also on the board of 9 other companies.

In the past Richard A. Heyman held the position of Vice President-Research at Ligand Pharmaceuticals, Inc., Senior Vice President-Drug Discovery at Kalypsys, Inc., President, CEO, Head-Research & Development at Aragon Pharmaceuticals, Inc. (he founded the company in 2009), President, Chief Executive Officer & Director at Seragon Pharmaceuticals, Inc. (he founded the company in 2013), Chief Scientific Officer & Senior VP-Research at X-Ceptor Therapeutics, Inc. (he founded the company in 1999) and Director at Syndax Pharmaceuticals, Inc.

He received an undergraduate degree from the University of Connecticut and a doctorate from the University of Minnesota.


Posti e reponsabilitą di Richard A. Heyman 
NomeTitolo Da
PMV Pharmaceuticals, Inc.
(Biotecnologia)
Chairman 2020
Gritstone bio, Inc.
(Prodotti farmaceutici)
Independent Director 2015
ORIC Pharmaceuticals, Inc.
(Biotecnologia)
Director -
Yumanity Therapeutics, Inc.
(Biotecnologia)
Independent Director -
Metacrine, Inc.
(Biotecnologia)
Chairman 2015
Amunix Pharmaceuticals, Inc. Chairman -
The Salk Institute for Biological Studies Vice Chairman 2015
BIOCOM Director -
Amunix, Inc. Director -
Jewish Federation of Omaha, Inc. Director -
American Association For Cancer Research Foundation Director -
Yumanity, Inc. Director -
Vividion Therapeutics, Inc. Director -
ARCH Venture Partners LLC Venture Partner -


Participazioni di Richard A. Heyman 
NomeAzioni%Valorizzazione
ORIC Pharmaceuticals, Inc. (ORIC)
(Biotecnologia)
228 7720,58%3 349 222 USD
Gritstone bio, Inc. (GRTS)
(Prodotti farmaceutici)
53 3230,083%586 020 USD
Tango Therapeutics, Inc. (TNGX)
(Biotecnologia)
40 6000,046%521 304 USD
Metacrine, Inc. (MTCR)
(Biotecnologia)
280 1911,06%397 871 USD
Yumanity Therapeutics, Inc. (YMTX)
(Biotecnologia)
6 1580,060%56 346 USD
PMV Pharmaceuticals, Inc. (PMVP)
(Biotecnologia)
00,0000%0 USD


Richard A. Heyman: network personale 
Le notizie pił lette 
24/11ELON MUSK: Musk vende azioni Tesla per 1,05 miliardi di dollari e compra 2,15 milioni di azioni
MR
24/11JAMIE DIMON: Jamie Dimon scherza sul fatto che JPMorgan sopravviverà al partito comunista cinese
MR
17/11ELON MUSK: Musk di Tesla vende altre 934.000 azioni per pagare le tasse dopo aver esercitato le opzioni - deposito
MR
16/11ELON MUSK: Musk di Tesla ha venduto 934.091 azioni per soddisfare gli obblighi di ritenuta fiscale - deposito
MR
24/11ERIK NORDSTROM: L'utile di Nordstrom manca le stime su problemi di supply-chain, le azioni crollano
MR
18/11MIUCCIA PRADA: Prada fissa un obiettivo di fatturato di 4,5 miliardi di euro, per aumentare l'e-commerce
MR
29/11JACK DORSEY: Twitter, si dimette Ceo Jack Dorsey
RE
29/11ANIL AMBANI: La banca centrale dell'India avvia la procedura di fallimento contro Reliance Capital; co per conformarsi
MR
23/11STUART ROSE: Gli azionisti di Morrisons appoggiano l'acquisizione di CD&R per 10 miliardi di dollari
MR
19/11AXEL WEBER: ESCLUSIVA - Ubs, Mustier in shortlist come successore presidente Weber - fonti
RE
Pił notizie


© 2021 People and Ownership :   
Richard A. Heyman : connessioni